NO993003D0 - Sulfonamid-derivater, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenter - Google Patents
Sulfonamid-derivater, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenterInfo
- Publication number
- NO993003D0 NO993003D0 NO993003A NO993003A NO993003D0 NO 993003 D0 NO993003 D0 NO 993003D0 NO 993003 A NO993003 A NO 993003A NO 993003 A NO993003 A NO 993003A NO 993003 D0 NO993003 D0 NO 993003D0
- Authority
- NO
- Norway
- Prior art keywords
- medicaments
- processes
- preparation
- sulfonamide derivatives
- sulfonamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9626377.7A GB9626377D0 (en) | 1996-12-19 | 1996-12-19 | Novel compounds |
GBGB9700901.3A GB9700901D0 (en) | 1997-01-17 | 1997-01-17 | Novel compounds |
GBGB9722757.3A GB9722757D0 (en) | 1997-10-27 | 1997-10-27 | Novel compounds |
PCT/EP1997/007159 WO1998027081A1 (en) | 1996-12-19 | 1997-12-15 | Sulphonamide derivatives, process for their preparation, and their use as medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
NO993003D0 true NO993003D0 (no) | 1999-06-18 |
NO993003L NO993003L (no) | 1999-06-18 |
Family
ID=27268644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO993003A NO993003L (no) | 1996-12-19 | 1999-06-18 | Sulfonamid-derivater, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenter |
Country Status (31)
Country | Link |
---|---|
US (2) | US6423717B1 (hu) |
EP (1) | EP0946539B1 (hu) |
JP (1) | JP2001506646A (hu) |
KR (1) | KR20000069554A (hu) |
CN (1) | CN1246116A (hu) |
AP (1) | AP1277A (hu) |
AR (1) | AR010795A1 (hu) |
AT (1) | ATE247099T1 (hu) |
AU (1) | AU729056B2 (hu) |
BG (1) | BG103530A (hu) |
BR (1) | BR9713734A (hu) |
CA (1) | CA2275492A1 (hu) |
CZ (1) | CZ220399A3 (hu) |
DE (1) | DE69724142T2 (hu) |
DZ (1) | DZ2376A1 (hu) |
EA (1) | EA002351B1 (hu) |
ES (1) | ES2203831T3 (hu) |
HU (1) | HUP0000658A3 (hu) |
ID (1) | ID22821A (hu) |
IL (1) | IL130297A0 (hu) |
MA (1) | MA24426A1 (hu) |
NO (1) | NO993003L (hu) |
NZ (1) | NZ335970A (hu) |
OA (1) | OA11066A (hu) |
PE (1) | PE46899A1 (hu) |
PL (1) | PL334337A1 (hu) |
SK (1) | SK80899A3 (hu) |
TR (1) | TR199901361T2 (hu) |
TW (1) | TW418205B (hu) |
UY (1) | UY24819A1 (hu) |
WO (1) | WO1998027081A1 (hu) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
HUP0003073A3 (en) | 1997-07-11 | 2002-10-28 | Smithkline Beecham Plc | Benzenesulfonamide derivatives, process for producing them and their use as medicines |
US6200995B1 (en) | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
GB9810671D0 (en) * | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
GB9818916D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
EP1248607A4 (en) * | 1999-12-21 | 2004-10-06 | Smithkline Beecham Corp | UROTENSIN II RECEPTOR ANTAGONISTS |
SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
SE0002739D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
US6399617B1 (en) | 2000-07-21 | 2002-06-04 | Biovitrum Ab | Use |
US6818639B2 (en) | 2000-07-21 | 2004-11-16 | Biovitrum Ab | Pharmaceutical combination formulation and method of treatment with the combination |
SE0002754D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
JP3847711B2 (ja) * | 2000-09-18 | 2006-11-22 | トーアエイヨー株式会社 | N置換ベンゾチオフェンスルホンアミド誘導体 |
US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
AU2002215047A1 (en) * | 2000-11-21 | 2002-06-03 | Smithkline Beecham Plc | Isoquinoline derivatives useful in the treatment of cns disorders |
US7132546B2 (en) | 2000-12-22 | 2006-11-07 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
AU2002256418A1 (en) * | 2001-04-27 | 2002-11-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
AR033879A1 (es) * | 2001-05-07 | 2004-01-07 | Smithkline Beecham Corp | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto |
US20050043536A1 (en) * | 2001-05-07 | 2005-02-24 | Dashyant Dhanak | Sulfonamides |
JP2004529164A (ja) * | 2001-05-07 | 2004-09-24 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
US6743796B2 (en) * | 2001-05-07 | 2004-06-01 | Wyeth | Piperazinyl-isatins |
JP2004535390A (ja) * | 2001-05-07 | 2004-11-25 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
EP1385830A4 (en) * | 2001-05-07 | 2005-08-17 | Smithkline Beecham Corp | SULPHONAMIDES |
GB0111186D0 (en) * | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
EP1406884A1 (en) | 2001-05-11 | 2004-04-14 | Biovitrum Ab | Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
RS88803A (en) * | 2001-05-11 | 2007-02-05 | Biovitrum Ab., | Novel-arylsulfonamide compounds for the treatment of obesity type ii diabetes and cns-disorders |
SK16052003A3 (en) | 2001-06-07 | 2004-10-05 | Hoffmann La Roche | New indole derivatives with 5-HT6 receptor affinity |
US7144883B2 (en) | 2001-06-11 | 2006-12-05 | Biovitrum Ab | Bicyclic sulfonamide compounds |
WO2002102774A1 (en) | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
US6727264B1 (en) * | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
EP1414442A1 (en) * | 2001-08-07 | 2004-05-06 | Smithkline Beecham Plc | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
DE60230424D1 (en) | 2001-08-10 | 2009-01-29 | Hoffmann La Roche | Arylsulfonyl-derivate mit 5-ht 6-rezeptor-affinität |
EP1433479B8 (en) * | 2001-09-05 | 2008-01-23 | Eisai R&D Management Co., Ltd. | Appetite-stimulating agents and remedies for anorexia |
SE0103644D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
WO2003039547A1 (en) * | 2001-11-09 | 2003-05-15 | Biovitrum Ab | Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake |
RS44304A (en) | 2001-11-22 | 2007-06-04 | Biovitrum Ab., | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
EA200400708A1 (ru) | 2001-11-22 | 2004-10-28 | Биовитрум Аб | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 |
MXPA04004981A (es) * | 2001-11-30 | 2004-08-11 | Hoffmann La Roche | Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma. |
EP1471912A1 (en) * | 2002-02-05 | 2004-11-03 | Glaxo Group Limited | Method of promoting neuronal growth |
EP1474401A2 (en) * | 2002-02-05 | 2004-11-10 | Novo Nordisk A/S | Novel aryl- and heteroarylpiperazines |
EP1495004A2 (en) * | 2002-02-13 | 2005-01-12 | Glaxo Group Limited | Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor ligands |
WO2003068751A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5-ht6 receptor affinity for the reatment of cns disorders |
WO2003068752A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | Benzenesulfonamide derivatives as antipsychotic agents |
WO2003080580A2 (en) | 2002-03-27 | 2003-10-02 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
US20040142948A1 (en) * | 2002-05-07 | 2004-07-22 | Dashyant Dhanak | Sulfonamides |
ATE316523T1 (de) * | 2002-05-13 | 2006-02-15 | Hoffmann La Roche | Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen |
JP4754821B2 (ja) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物 |
EP1513828A1 (en) * | 2002-06-20 | 2005-03-16 | Biovitrum AB | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
EP1897881A3 (en) | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
ES2274285T3 (es) | 2002-10-18 | 2007-05-16 | F. Hoffmann-La Roche Ag | 4-piperanzinilbencenosulfonilindoles con afinidad al receptor 5-ht6. |
WO2004043368A2 (en) * | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
AU2003291262A1 (en) * | 2002-11-06 | 2004-06-03 | Smithkline Beecham Corporation | Sulfonamides |
NZ540612A (en) | 2003-01-14 | 2008-02-29 | Arena Pharm Inc | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
US7153858B2 (en) | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
JP2006518718A (ja) * | 2003-02-13 | 2006-08-17 | ランクセス ドイチュラント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 光学データ記録媒体の情報層における吸光性化合物としての金属錯体 |
EP1610753A4 (en) * | 2003-02-20 | 2007-07-04 | Encysive Pharmaceuticals Inc | UROTENSIN-II RECEPTOR ANTAGONISTS OF PHENYLENEDIAMINE AND ANTAGONISTS OF CCR-9 |
TWI289141B (en) * | 2003-03-11 | 2007-11-01 | Hoffmann La Roche F. Ag. | Quinolinone derivatives and uses thereof |
WO2004087654A2 (en) * | 2003-03-31 | 2004-10-14 | Janssen Pharmaceutica N.V. | Phospholipase c inhibitors for use in treating inflammatory disorders |
US6946466B2 (en) * | 2003-04-10 | 2005-09-20 | Schering Ag | Aromatic sulfonamides as peroxynitrite-rearrangement catalysts |
US20040204422A1 (en) * | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
CN1826322B (zh) | 2003-07-22 | 2012-04-18 | 艾尼纳制药公司 | 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物 |
GB0320320D0 (en) * | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
EA010298B1 (ru) * | 2003-12-19 | 2008-08-29 | Биовитрум Аб (Пабл) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором |
BRPI0513713A (pt) * | 2004-07-28 | 2008-05-13 | Glaxo Group Ltd | derivados de piperazina úteis para o tratamento de distúrbios gastrointestinais |
CA2582273C (en) * | 2004-09-30 | 2013-10-29 | Douglas William Bonhaus | Compositions and methods for treating cognitive disorders using serotonin receptor antagonists |
WO2006040176A1 (en) | 2004-10-14 | 2006-04-20 | Abbott Gmbh & Co. Kg | Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
ES2364488T3 (es) * | 2004-10-14 | 2011-09-05 | ABBOTT GMBH & CO. KG | Compuestos heterocíclicos adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina. |
WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
EP1676841A1 (en) * | 2004-12-30 | 2006-07-05 | Esteve Laboratorios Dr. Esteve S.A. | Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments |
KR100931928B1 (ko) * | 2005-01-12 | 2009-12-15 | 인제대학교 산학협력단 | P25/cdk5 저해 화합물을 포함하는 퇴행성 뇌질환의 예방 및치료용 약학 조성물 |
EP2233470B1 (en) | 2005-07-04 | 2011-12-07 | High Point Pharmaceuticals, LLC | Histamine H3 receptor antagonists |
CN101258144B (zh) | 2005-08-12 | 2012-05-30 | 苏文生命科学有限公司 | 作为功能性5-ht6配体的氨基芳基磺酰胺衍生物 |
WO2007020654A1 (en) | 2005-08-16 | 2007-02-22 | Suven Life Sciences | An improved process for the preparation of losartan |
WO2007076875A2 (en) * | 2006-01-06 | 2007-07-12 | Aarhus Universitet | Compounds acting on the serotonin transporter |
EP2013178A1 (en) | 2006-03-31 | 2009-01-14 | Glaxo Group Limited | Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists |
EP2074110A1 (en) | 2006-04-19 | 2009-07-01 | Abbott GmbH & Co. KG | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
AU2007239494A1 (en) * | 2006-04-19 | 2007-10-25 | Abbott Gmbh & Co. Kg | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor |
JP2009537596A (ja) | 2006-05-23 | 2009-10-29 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 6−(4−シクロプロピルピペリジン−1−イル)−2’−メチル−[3,4’]−ビピリジン及びその医薬としての使用 |
SG163547A1 (en) | 2006-05-29 | 2010-08-30 | High Point Pharmaceuticals Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
US7906555B2 (en) | 2006-10-26 | 2011-03-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
EP2114878B1 (en) | 2007-01-08 | 2010-12-15 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
EP2118062A1 (en) * | 2007-01-10 | 2009-11-18 | F. Hoffmann-Roche AG | Sulfonamide derivatives as chymase inhibitors |
KR20090123977A (ko) | 2007-03-23 | 2009-12-02 | 애보트 게엠베하 운트 콤파니 카게 | 세로토닌 5-ht6 수용체의 조절에 반응하는 장애를 치료하는데 적합한 아제티딘 화합물 |
CA2683124C (en) | 2007-05-03 | 2012-09-25 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands |
EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
DE602007012683D1 (de) * | 2007-07-19 | 2011-04-07 | Esteve Labor Dr | Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente |
JP5236001B2 (ja) | 2007-10-26 | 2013-07-17 | スヴェン・ライフ・サイエンシズ・リミテッド | アミノアリールスルホンアミド化合物および5−ht6リガンドとしてのその使用 |
PA8802201A1 (es) * | 2007-11-02 | 2009-06-23 | Abbott Gmbh & Co Kg | Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US20110034565A1 (en) | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
WO2009152356A2 (en) * | 2008-06-11 | 2009-12-17 | Irm Llc | Compounds and compositions useful for the treatment of malaria |
EA019496B1 (ru) | 2008-09-17 | 2014-04-30 | Сувен Лайф Сайенсиз Лимитед | Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht |
WO2010032257A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
UA100192C2 (en) | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
KR101073703B1 (ko) | 2009-04-07 | 2011-10-14 | 한국화학연구원 | 피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물 |
US8183237B2 (en) | 2009-04-30 | 2012-05-22 | Abbott Laboratories | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
WO2010125136A1 (en) * | 2009-04-30 | 2010-11-04 | Abbott Gmbh & Co. Kg | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
ES2536779T3 (es) | 2009-04-30 | 2015-05-28 | Abbvie Deutschland Gmbh & Co Kg | Compuestos de N-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-HT6 |
US8343959B2 (en) | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
NZ601284A (en) | 2010-01-05 | 2014-03-28 | Suven Life Sciences Ltd | Sulfone compounds as 5-ht6 receptor ligands |
EP2619198A1 (en) | 2010-09-22 | 2013-07-31 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012059431A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
WO2012059432A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
ES2413911B1 (es) * | 2011-12-15 | 2014-05-14 | Universidad De Zaragoza | Agente inhibidor de la agregación del peptido beta amiloide. |
KR20140135835A (ko) | 2012-03-20 | 2014-11-26 | 아다메드 에스피. 제트 오.오. | Cns 질환의 치료를 위한 벤질아민의 설폰아미드 유도체 |
JP6433974B2 (ja) | 2013-03-14 | 2018-12-05 | トレロ ファーマシューティカルズ, インコーポレイテッド | Jak2およびalk2阻害剤およびその使用方法 |
RU2688161C2 (ru) | 2013-07-25 | 2019-05-20 | Университет Ягеллоньски | Пирролохинолиновые производные в качестве 5-нт6 антагонистов, способ их получения и применение |
CN105085436B (zh) | 2014-04-19 | 2019-08-16 | 广东东阳光药业有限公司 | 磺酰胺类衍生物及其在药物上的应用 |
CN105367472B (zh) * | 2014-08-12 | 2020-04-21 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
CN105367473B (zh) * | 2014-08-12 | 2020-02-11 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
EP4445956A2 (en) | 2015-01-06 | 2024-10-16 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
AU2016276966A1 (en) | 2015-06-12 | 2018-01-18 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder |
WO2016209809A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders |
TW201720439A (zh) | 2015-07-15 | 2017-06-16 | Axovant Sciences Gmbh | 用於預防及治療與神經退化性疾病相關的幻覺之作為5-ht2a血清素受體的二芳基及芳基雜芳基脲衍生物 |
CN108926565A (zh) * | 2017-05-26 | 2018-12-04 | 中国科学院上海生命科学研究院 | 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用 |
WO2019180176A1 (en) | 2018-03-21 | 2019-09-26 | Spherium Biomed, S.L. | Composition for the treatment of schizophrenia and/or psychosis |
JP2021530554A (ja) | 2018-07-26 | 2021-11-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE81861C (hu) | ||||
NZ193654A (en) * | 1979-05-16 | 1984-08-24 | Wuelfing Johann A | Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions |
US4315014A (en) * | 1980-09-24 | 1982-02-09 | Warner-Lambert Company | Antibacterial amide compounds and pharmaceutical composition containing the same |
DE3276313D1 (en) * | 1981-09-24 | 1987-06-19 | Beecham Wuelfing Gmbh & Co Kg | Sulphonamides |
CN85106905A (zh) * | 1985-08-08 | 1987-02-04 | Fmc公司 | 含有1-芳基-δ2-1,2,4,-三唑啉-5-酮类的除草剂及其制备方法 |
WO1990009787A1 (en) * | 1989-02-27 | 1990-09-07 | The Du Pont Merck Pharmaceutical Company | Novel sulfonamides as radiosensitizers |
JPH04330057A (ja) * | 1991-05-01 | 1992-11-18 | Hiroyoshi Hidaka | アニリンアリールスルホン酸アミド類及び薬剤として許容され得るその酸付加塩 |
GB9119932D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
DE4206531A1 (de) * | 1992-03-02 | 1993-09-09 | Bayer Ag | N-aryl-stickstoffheterocyclen |
DE4303376A1 (de) * | 1993-02-05 | 1994-08-11 | Bayer Ag | Substituierte Triazolinone |
WO1995006637A1 (en) * | 1993-09-03 | 1995-03-09 | Smithkline Beecham Plc | Indole and indoline derivatives as 5ht1d receptor antagonists |
JPH09503773A (ja) * | 1993-10-19 | 1997-04-15 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5ht−1dレセプター拮抗剤用のベンズアニリド誘導体 |
AU1108395A (en) * | 1993-12-07 | 1995-06-27 | Smithkline Beecham Plc | Heterocyclic biphenylylamides useful as 5ht1d antagonists |
US5756496A (en) * | 1994-05-28 | 1998-05-26 | Smithkline Beecham P.L.C. | Amide derivatives having 5HT1D-antagonist activity |
US5939451A (en) | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
-
1997
- 1997-12-07 DZ DZ970226A patent/DZ2376A1/xx active
- 1997-12-15 SK SK808-99A patent/SK80899A3/sk unknown
- 1997-12-15 EA EA199900561A patent/EA002351B1/ru not_active IP Right Cessation
- 1997-12-15 BR BR9713734-0A patent/BR9713734A/pt not_active IP Right Cessation
- 1997-12-15 HU HU0000658A patent/HUP0000658A3/hu unknown
- 1997-12-15 NZ NZ335970A patent/NZ335970A/en unknown
- 1997-12-15 CN CN97181816A patent/CN1246116A/zh active Pending
- 1997-12-15 WO PCT/EP1997/007159 patent/WO1998027081A1/en not_active Application Discontinuation
- 1997-12-15 JP JP52734798A patent/JP2001506646A/ja not_active Ceased
- 1997-12-15 ES ES97954929T patent/ES2203831T3/es not_active Expired - Lifetime
- 1997-12-15 AU AU60904/98A patent/AU729056B2/en not_active Ceased
- 1997-12-15 IL IL13029797A patent/IL130297A0/xx unknown
- 1997-12-15 AT AT97954929T patent/ATE247099T1/de not_active IP Right Cessation
- 1997-12-15 KR KR1019997005497A patent/KR20000069554A/ko not_active Application Discontinuation
- 1997-12-15 CZ CZ992203A patent/CZ220399A3/cs unknown
- 1997-12-15 EP EP97954929A patent/EP0946539B1/en not_active Expired - Lifetime
- 1997-12-15 PL PL97334337A patent/PL334337A1/xx unknown
- 1997-12-15 AP APAP/P/1999/001556A patent/AP1277A/en active
- 1997-12-15 CA CA002275492A patent/CA2275492A1/en not_active Abandoned
- 1997-12-15 TR TR1999/01361T patent/TR199901361T2/xx unknown
- 1997-12-15 ID IDW990546A patent/ID22821A/id unknown
- 1997-12-15 DE DE69724142T patent/DE69724142T2/de not_active Expired - Fee Related
- 1997-12-17 PE PE1997001126A patent/PE46899A1/es not_active Application Discontinuation
- 1997-12-17 MA MA24902A patent/MA24426A1/fr unknown
- 1997-12-17 AR ARP970105951A patent/AR010795A1/es not_active Application Discontinuation
- 1997-12-18 UY UY24819A patent/UY24819A1/es not_active Application Discontinuation
- 1997-12-18 TW TW086119136A patent/TW418205B/zh not_active IP Right Cessation
-
1999
- 1999-06-18 OA OA9900133A patent/OA11066A/en unknown
- 1999-06-18 NO NO993003A patent/NO993003L/no not_active Application Discontinuation
- 1999-06-25 BG BG103530A patent/BG103530A/bg unknown
-
2000
- 2000-08-21 US US09/643,200 patent/US6423717B1/en not_active Expired - Fee Related
-
2002
- 2002-05-29 US US10/157,258 patent/US6599904B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO993003L (no) | Sulfonamid-derivater, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenter | |
NO991815D0 (no) | Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter | |
NO20012058L (no) | 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler | |
NO20020811D0 (no) | Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler | |
NO20011503L (no) | Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler | |
DK0676409T3 (da) | Erythromycinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler | |
NO20020684L (no) | 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler | |
NO20006029D0 (no) | Pyrazolinderivater, deres fremstilling og anvendelse som legemidler | |
DK1538160T3 (da) | Substituerede isochinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel | |
NO20011216L (no) | Azetidinderivater, deres fremstilling og medikamenter inneholdende forbindelsene | |
NO20005146L (no) | Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter | |
NO963506D0 (no) | 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler | |
DK0877745T3 (da) | N-([1,2,4]triazoloazinyl)benzensulfonamid- og pyridinsulfonamidforbindelser og deres anvendelse som herbicider | |
DK1095025T3 (da) | Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler | |
NO20006251D0 (no) | Benzotiepin-1,1-dioksidderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse | |
NO20002217D0 (no) | Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler | |
NO20006138L (no) | Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter | |
NO20000294L (no) | Derivater av acylpiperazinylpyrimidiner, deres fremstilling og anvendelse som legemidler | |
NO985307D0 (no) | Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvendelse som antitumor- og antivirale midler | |
DK0795547T3 (da) | (Aminoalkyl- og acylaminoalkyl-oxy)benzyloxyquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse som bradyk | |
NO951418D0 (no) | Peptidderivater, deres fremstilling og anvendelse som terapeutika | |
NO20010219L (no) | Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel | |
NO960272D0 (no) | Oksatiolaner, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder de samme | |
DK0763535T3 (da) | Piperidinylmethyloxazolidin-2-on-derivater, deres fremstilling og deres anvendelse som centralnervesystem-aktive forbindelser | |
NO20002959L (no) | Echinocandinderivater, fremgangsmÕte for fremstilling av slike og deres anvendelse som anti-soppmidler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |